Eli Lilly and Company (LLY MU) stock market data APIs
€1305.1547
0(0%)
as of November 13, 2026
Try our APIs with
free plan!
Eli Lilly and Company Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for LLY.MU.
Prev. Close
1305.1547
Open
1305.1547
High
1305.1547
Low
1305.1547
52 wk Range
726.2309-1321.6088
Market Cap
206 794 M
P/E Ratio
49.0916
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eli Lilly and Company data using free add-ons & libraries
Get Eli Lilly and Company Fundamental Data
Eli Lilly and Company Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 26
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-10-29
- EPS/Forecast: 6.61
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eli Lilly and Company News
New
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes...
What Eli Lilly Doubters Overlooked
If you only glanced at Eli Lilly's headlines this year, the drumbeat of new GLP-1 data, obesity trial wins, and fresh acquisitions might feel almost routine. Investors who held Eli Lilly over the past...
Weekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields Climb
VANCOUVER, BC, Nov. 13, 2026 /PRNewswire/ -- Stock Preachers News Commentary - Wall Street closed out a volatile week with every major index still higher versus last Friday, even after a broad Friday ...
HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
Hims & Hers Health, Inc. HIMS has partnered with Eli Lilly and Company LLY to expand patient access to Lilly's FDA-approved obesity treatments, Zepbound and Foundayo, through its digital health platfo...
Get Eli Lilly and Company fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.